Senior Leadership Appointments Strengthen Trajan’s Global Direction

Senior Leadership Appointments Strengthen Trajan’s Global Direction

October 17, 2013

Trajan Scientific and Medical (Trajan) has enhanced its global leadership team with a number of key appointments:

  • Dr Harry Ritchie, formerly Director of Technology and Business Development at ThermoFisher Scientific has joined Trajan as Director of Operations in Europe, based in the UK.
  • Glenn Clivaz, formerly Director of SGE Analytical Science has relocated from Melbourne, Australia to Boston, MA, USA as Trajan’s Director of Operations for the Americas.
  • Mike Bailey, formerly General Manager of Upchurch Scientific has joined Trajan as Director of Business Development, based in Seattle, WA, USA.
  • Rob Lyon, a senior legal and finance advisor has joined Trajan as Head of Corporate Development, based in Melbourne, Australia.
  • John Dwyer, formerly Commercial and Marketing Manager at Lomb Scientific then Category Manager at ThermoFisher Scientific, is based in Sydney, Australia, and is leading the commercial development of Trajan’s pathology consumables company, Grale HDS.
  • David Elks, with over 30 years manufacturing expertise including positions at General Motors Holden, Dunlop Aerospace Technologies and SGE Analytical Science, is General Manager of SciMed Precision, Trajan’s precision machining company based in Melbourne, Australia.

Trajan’s leadership team also includes Anthony Audino, Vice President Global Business Development, Makoto Ohashi, Director Asia, Dr Andrew Gooley, Chief Scientific Officer, Alister Hodges, Chief Financial Officer, Mark Power, Global Quality and Continuous Improvement Manager, Hélène Lajoie, Global HR Manager, and Chris Clapham, Global Marketing Communications Manager.

Commenting on his growing team, Stephen Tomisich, Trajan’s Chief Executive Officer said, “We are building a strong, global commercial and technical team. We are proud that our core customers are some of the leading global enterprises in our industry. If we are to serve them at a standard beyond expectations then we must put in place the best team of people that we can gather; and that’s what we are doing.”

Trajan, formed in 2011, encompasses a group of companies including SGE Analytical Science, Grale HDS and SciMed Precision with over 300 staff worldwide. Trajan’s commitment to people development at all levels is essential to its success as a global operation.

We believe that we are in a unique position to develop technologies that will deliver more sensitive,
selective and affordable analysis in biological, food and environmental applications.
” said Mr Tomisich.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More